Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Neurological Sciences
Published in: Neurological Sciences 2/2021

01-02-2021 | Epilepsy | Review Article

MicroRNAs in temporal lobe epilepsy: a systematic review

Authors: Ali A. Asadi-Pooya, Amir Tajbakhsh, Amir Savardashtaki

Published in: Neurological Sciences | Issue 2/2021

Login to get access

Abstract

Objective

About 30% of patients with epilepsy have drug-resistant seizures. The aim of the current endeavor was to systematically review the existing evidence on the potential applications of microRNAs as biomarkers in people with difficult to treat temporal lobe epilepsy (TLE).

Methods

MEDLINE (accessed from PubMed) and Scopus from inception to March 18, 2020 were systematically searched for related published articles. In both electronic databases, the following search strategy was implemented, and these keywords (in the title/abstract) were used: “microRNA” AND “temporal lobe epilepsy.” Articles written in English that were human studies in people with epilepsy were all included in this search.

Results

We could identify 16 articles about different aspects of microRNAs in the serum of patients with TLE. However, only three studies robustly investigated microRNAs as potential biomarkers in the diagnosis of drug-resistant TLE (microRNA-155 (upregulated), microRNA-129-2-3p (upregulated), microRNA-153 (downregulated)). One small study provided class II, and two small studies provided class III evidence.

Conclusion

While this systematic review identified three studies that provided some evidence on the potential applications of circulating serum microRNAs as biomarkers in people with drug-resistant TLE, the evidence is not robust yet. While these findings provide a new horizon, substantial challenges remain before the roles of microRNAs as biomarkers in the diagnosis of drug-resistant TLE can be translated into clinical practice.
Appendix
Available only for authorised users
Literature
1.
2.
Asadi-Pooya AA & Sperling MR (2016) Antiepileptic drugs: a clinician’s manual. Second Edition. New York, Oxford University Press
3.
4.
Engel J Jr, McDermott MP, Wiebe S, Langfitt JT, Stern JM, Dewar S et al (2012) Early surgical therapy for drug-resistant temporal lobe epilepsy: a randomized trial. JAMA 307:922–930PubMedPubMedCentralCrossRef
5.
Asadi-Pooya AA, Stewart GR, Abrams DJ, Sharan A (2017) Prevalence and incidence of drug-resistant mesial temporal lobe epilepsy in the United States. World Neurosurg 99:662–666PubMedCrossRef
6.
Kuzmanovski I, Cvetkovska E, Babunovska M, Kiteva Trencevska G, Kuzmanovska B, Boshkovski B, Isjanovska R (2016) Seizure outcome following medical treatment of mesial temporal lobe epilepsy: clinical phenotypes and prognostic factors. Clin Neurol Neurosurg 144:91–95PubMedCrossRef
7.
Mathon B, Bédos Ulvin L, Adam C, Baulac M, Dupont S, Navarro V, Cornu P, Clemenceau S (2015) Surgical treatment for mesial temporal lobe epilepsy associated with hippocampal sclerosis. Rev Neurol (Paris) 171(3):315–325CrossRef
8.
9.
Radhakrishnan A, Menon R, Thomas SV, Abraham M, Vilanilam G, Kesavadas C, Thomas B, Cherian A, Varma RP (2018) “Time is Brain”-how early should surgery be done in drug-resistant TLE? Acta Neurol Scand 138:531–540PubMedCrossRef
10.
11.
12.
Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JPA, Straus S, Thorlund K, Jansen JP, Mulrow C, Catalá-López F, Gøtzsche PC, Dickersin K, Boutron I, Altman DG, Moher D (2015) The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 162:777–784PubMedCrossRef
13.
Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097PubMedPubMedCentralCrossRef
14.
Gronseth GS, Cox J, Gloss D, Merillat S, Dittman J, Armstrong MJ, et al. on behalf of the Guideline Development (2017) Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Clinical practice guideline process manual, 2017 ed. Minneapolis, MN: The American Academy of Neurology
15.
Avansini SH, de Sousa Lima BP, Secolin R, Santos ML, Coan AC, Vieira AS, Torres FR, Carvalho BS, Alvim MKM, Morita ME, Yasuda CL, Pimentel-Silva LR, Dogini DB, Rogerio F, Cendes F, Lopes-Cendes I (2017) MicroRNA hsa-miR-134 is a circulating biomarker for mesial temporal lobe epilepsy. PLoS One 12:e0173060PubMedPubMedCentralCrossRef
16.
Duan W, Chen Y, Wang XR (2018) MicroRNA-155 contributes to the occurrence of epilepsy through the PI3K/Akt/mTOR signaling pathway. Int J Mol Med 42:1577–1584PubMed
17.
Gong GH, An FM, Wang Y, Bian M, Wang D, Wei CX (2018) Comprehensive circular RNA profiling reveals the regulatory role of the CircRNA-0067835/miR-155 pathway in temporal lobe epilepsy. Cell Physiol Biochem 51:1399–1409PubMedCrossRef
18.
Li Y, Huang C, Feng P, Jiang Y, Wang W, Zhou D, Chen L (2016) Aberrant expression of miR-153 is associated with overexpression of hypoxia-inducible factor-1α in refractory epilepsy. Sci Rep 6:32091PubMedPubMedCentralCrossRef
19.
Manna I, Labate A, Mumoli L, Pantusa M, Ferlazzo E, Aguglia U, Quattrone A, Gambardella A (2013) Relationship between genetic variant in pre-microRNA-146a and genetic predisposition to temporal lobe epilepsy: a case-control study. Gene 516:181–183PubMedCrossRef
20.
Raoof R, Bauer S, El Naggar H, Connolly NMC, Brennan GP, Brindley E et al (2018) Dual-center, dual-platform microRNA profiling identifies potential plasma biomarkers of adult temporal lobe epilepsy. EBioMedicine 38:127–141PubMedPubMedCentralCrossRef
21.
Sun Y, Wang X, Wang Z, Zhang Y, Che N, Luo X, Tan Z, Sun X, Li X, Yang K, Wang G, Luan L, Liu Y, Zheng X, Wei M, Cheng H, Yin J (2016) Expression of microRNA-129-2-3p and microRNA-935 in plasma and brain tissue of human refractory epilepsy. Epilepsy Res 127:276–283PubMedCrossRef
22.
Surges R, Kretschmann A, Abnaof K, van Rikxoort M, Ridder K, Fröhlich H, Danis B, Kaminski RM, Foerch P, Elger CE, Weinsberg F, Pfeifer A (2016) Changes in serum miRNAs following generalized convulsive seizures in human mesial temporal lobe epilepsy. Biochem Biophys Res Commun 481:13–18PubMedCrossRef
23.
Xiao W, Cao Y, Long H, Luo Z, Li S, Deng N, Wang J, Lu X, Wang T, Ning S, Wang L, Xiao B (2018) Genome-wide DNA methylation patterns analysis of noncoding RNAs in temporal lobe epilepsy patients. Mol Neurobiol 55:793–803PubMedCrossRef
24.
Yan S, Zhang H, Xie W, Meng F, Zhang K, Jiang Y, Zhang X, Zhang J (2017) Altered microRNA profiles in plasma exosomes from mesial temporal lobe epilepsy with hippocampal sclerosis. Oncotarget 8:4136–4146PubMedCrossRef
25.
Antônio LGL, Freitas-Lima P, Pereira-da-Silva G, Assirati JA Jr, Matias CM, Cirino MLA, Tirapelli LF, Velasco TR, Sakamoto AC, Carlotti CG Jr, Tirapelli DPC (2019) Expression of microRNAs miR-145, miR-181c, miR-199a and miR-1183 in the blood and hippocampus of patients with mesial temporal lobe epilepsy. J Mol Neurosci 69:580–587PubMedCrossRef
26.
De Matteis M, Cecchetto G, Munari G, Balsamo L, Gardiman MP, Giordano R et al (2018) Circulating miRNAs expression profiling in drug-resistant epilepsy: Up-regulation of miR-301a-3p in a case of sudden unexpected death. Leg Med (Tokyo) 31:7–9CrossRef
27.
Manna I, Labate A, Borzì G, Mumoli L, Cavalli SM, Sturniolo M, Quattrone A, Gambardella A (2016) An SNP site in pri-miR-124, a brain expressed miRNA gene, no contribution to mesial temporal lobe epilepsy in an Italian sample. Neurol Sci 37:1335–1339PubMedCrossRef
28.
Shen CH, Zhang YX, Zheng Y, Yang F, Hu Y, Xu S, Yan SQ, Ding Y, Guo Y, Ding MP (2019) Expression of plasma microRNA-145-5p and its correlation with clinical features in patients with refractory epilepsy. Epilepsy Res 154:21–25PubMedCrossRef
29.
Gong GH, An FM, Wang Y, Bian M, Wang D, Wei CX (2018) MiR-153 regulates expression of hypoxia-inducible factor-1α in refractory epilepsy. Oncotarget 9:8542–8547PubMedPubMedCentralCrossRef
30.
Raoof R, Jimenez-Mateos EM, Bauer S, Tackenberg B, Rosenow F, Lang J, Onugoren MD, Hamer H, Huchtemann T, Körtvélyessy P, Connolly NMC, Pfeiffer S, Prehn JHM, Farrell MA, O’Brien DF, Henshall DC, Mooney C (2017) Cerebrospinal fluid microRNAs are potential biomarkers of temporal lobe epilepsy and status epilepticus. Sci Rep 7:3328PubMedPubMedCentralCrossRef
31.
Fan X, Heijnen CJ, van der Kooij MA, Groenendaal F, van Bel F (2009) The role and regulation of hypoxia-inducible factor-1alpha expression in brain development and neonatal hypoxic-ischemic brain injury. Brain Res Rev 62:99–108PubMedCrossRef
32.
Wang G, Xie G, Han L, Wang D, Du F, Kong X et al (2019) Involvement of hypoxia-inducible factor-1 alpha in the upregulation of P-glycoprotein in refractory epilepsy. Neuroreport 30:1191–1196PubMedCrossRef
33.
Tang F, Hartz AMS, Bauer B (2017) Drug-resistant epilepsy: multiple hypotheses. Few Answers. Front Neurol 8:301PubMedCrossRef
34.
Tishler DM, Weinberg KI, Hinton DR, Barbaro N, Annett GM, Raffel C (1995) MDR 1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia 36:1–6PubMedCrossRef
35.
Feldmann M, Asselin MC, Liu J, Wang S, McMahon A, Anton-Rodriguez J, Walker M, Symms M, Brown G, Hinz R, Matthews J, Bauer M, Langer O, Thom M, Jones T, Vollmar C, Duncan JS, Sisodiya SM, Koepp MJ (2013) P-glycoprotein expression and function in patients with temporal lobe epilepsy: a case-control study. Lancet Neurol 12(8):777–785PubMedCrossRef
36.
Volk HA, Burkhardt K, Potschka H, Chen J, Becker A, Loscher W (2004) Neuronal expression of the drug efflux transporter P-glycoprotein in the rat hippocampus after limbic seizures. Neuroscience 123:751–759PubMedCrossRef
37.
Asadi-Pooya AA, Razavizadegan SM, Abdi-Ardekani A, Sperling MR (2013) Adjunctive use of verapamil in patients with refractory temporal lobe epilepsy: a pilot study. Epilepsy Behav 29:150–154PubMedCrossRef
38.
Huang LG, Zou J, Lu QC (2018) Silencing rno-miR-155-5p in rat temporal lobe epilepsy model reduces pathophysiological features and cell apoptosis by activating Sestrin-3. Brain Res 1689:109–122PubMedCrossRef
39.
Li TR, Jia YJ, Wang Q, Shao XQ, Zhang P, Lv RJ (2018) Correlation between tumor necrosis factor alpha mRNA and microRNA-155 expression in rat models and patients with temporal lobe epilepsy. Brain Res 1700:56–65PubMedCrossRef
40.
Zupcic SG, Zupcic M, Duzel V, Simurina T, Sakic L, Grubjesic I, Tonković D, Udovic IS, Ferreri VM (2020) The potential role of micro-RNA-211 in the pathogenesis of sleep-related hypermotor epilepsy. Med Hypotheses 143:110115PubMedCrossRef
41.
Alsharafi W, Xiao B (2015) Dynamic expression of MicroRNAs (183, 135a, 125b, 128, 30c and 27a) in the rat pilocarpine model and temporal lobe epilepsy patients. CNS Neurol Disord Drug Targets 14:1096–1102PubMedCrossRef
42.
Henshall DC, Hamer HM, Pasterkamp RJ, Goldstein DB, Kjems J, Prehn JHM, Schorge S, Lamottke K, Rosenow F (2016) MicroRNAs in epilepsy: pathophysiology and clinical utility. Lancet Neurol 15:1368–1376PubMedCrossRef
43.
44.
Zhang H, Lian Y, Xie N, Cheng X, Chen C, Xu H, Zheng Y (2020) Antagomirs targeting miR-142-5p attenuate pilocarpine-induced status epilepticus in mice. Exp Cell Res 393:112089PubMedCrossRef
45.
Metadata
Title
MicroRNAs in temporal lobe epilepsy: a systematic review
Authors
Ali A. Asadi-Pooya
Amir Tajbakhsh
Amir Savardashtaki
Publication date
01-02-2021
Publisher
Springer International Publishing
Published in
Neurological Sciences / Issue 2/2021
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-020-05016-x

Other articles of this Issue 2/2021

Neurological Sciences 2/2021 Go to the issue

COVID-19

Down’s syndrome and COVID-19: risk or protection factor against infection? A molecular and genetic approach

Review Article

Magnetic resonance-guided focused ultrasound for Parkinson’s disease since ExAblate, 2016–2019: a systematic review

Brief Communication

Is DAT imaging abnormality in normal pressure hydrocephalus always suggestive of degeneration?

Original Article

Neuropsychiatric symptoms and striatal monoamine availability in early Parkinson’s disease without dementia

Quiz Cases

A novel missense pathogenic variant in NEFH causing rare Charcot-Marie-Tooth neuropathy type 2CC

Original Article

Evaluation of serum uric levels in migraine